Skip to main content
. Author manuscript; available in PMC: 2007 Dec 17.
Published in final edited form as: J Clin Oncol. 2006 May 20;24(15):2283–2289. doi: 10.1200/JCO.2005.04.5716

Fig 1.

Fig 1

The interval from last dose of ipilimumab (MDX-010) to the onset of symptoms of enterocolitis. An interval of 0 days indicates a patient who received ipilimumab while having some symptoms, and those with intervals of more than 21 days had stopped ipilimumab dosing but went on to develop enterocolitis later.